Anemia (phenotype)

12

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

Anemia (phenotype) is an emerging landscape with 12 programs across 9 companies.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Pipeline

Preclinical12

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Luspatercept

Bristol-Myers Squibb

Potassium Iodide

Meda Pharmaceuticals

Roxadustat

Astellas

Epoetin Beta

Roche

Phase 1

No programs

Phase 2

No programs

Phase 3

No programs

Approved

No programs

Analysis

90%

Small molecule

9 of 10 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)